Trademark: IMMEDIATE IMMUNITY 969110
Word
IMMEDIATE IMMUNITY
ID
969110
Trademark Type
Word
Status
Lapsed: Not accepted
Application Date
08 September 2003
Service
Davies Collison Cave Pty Ltd
Goods and Services:
Class 1:
Biochemicals, namely, monoclonal antibodies and fragments thereof, for research, development and manufacturing of pharmaceuticals; cell lines for use in the manufacture of pharmaceuticals; biochemical products for use in the development of vaccines, namely therapeutic vaccines, polypeptide, viral and nucleic acids vaccines, antibodies, polypeptides, protein and nucleic acids for vaccine use; and vaccine excipients, vaccine carriers and vaccine adjuvants for medical science
Biochemicals, namely, monoclonal antibodies and fragments thereof, for research, development and manufacturing of pharmaceuticals; cell lines for use in the manufacture of pharmaceuticals; biochemical products for use in the development of vaccines, namely therapeutic vaccines, polypeptide, viral and nucleic acids vaccines, antibodies, polypeptides, protein and nucleic acids for vaccine use; and vaccine excipients, vaccine carriers and vaccine adjuvants for medical science
Class 5:
Biochemicals, namely, monoclonal antibodies and fragments thereof, for clinical, diagnostic and therapeutic use for the treatment or prevention of infectious diseases, biowarfare exposure, inflammatory diseases, immune diseases, and genetic diseases; cell lines for clinical, diagnostic and therapeutic use for the treatment or prevention of infectious diseases, biowarfare exposure, inflammatory diseases, immune diseases, and genetic diseases; vaccines, namely, therapeutic vaccines, polypeptide vaccines, live vaccines, viral vaccines, nucleic acid vaccines, vaccines containing antibodies, polypeptides, protein and nucleic acids, vaccine recipients, vaccine carriers, and vaccines adjuvants
Biochemicals, namely, monoclonal antibodies and fragments thereof, for clinical, diagnostic and therapeutic use for the treatment or prevention of infectious diseases, biowarfare exposure, inflammatory diseases, immune diseases, and genetic diseases; cell lines for clinical, diagnostic and therapeutic use for the treatment or prevention of infectious diseases, biowarfare exposure, inflammatory diseases, immune diseases, and genetic diseases; vaccines, namely, therapeutic vaccines, polypeptide vaccines, live vaccines, viral vaccines, nucleic acid vaccines, vaccines containing antibodies, polypeptides, protein and nucleic acids, vaccine recipients, vaccine carriers, and vaccines adjuvants
Class 42:
Scientific, pharmaceutical and biological product development consultation, namely development consultation for vaccines and vaccine-related products; pharmaceutical and biological product development for others; vaccine and immunotherapy research and development; pharmaceutical, biomedical and biotechnological development of therapeutic vaccines and antibody-based products
Scientific, pharmaceutical and biological product development consultation, namely development consultation for vaccines and vaccine-related products; pharmaceutical and biological product development for others; vaccine and immunotherapy research and development; pharmaceutical, biomedical and biotechnological development of therapeutic vaccines and antibody-based products